All patients scheduled for anthracycline-containing therapy for various kinds of tumors
Conditions
Interventions
Echocardiac examination (before &
during anthracycline treatment, after 3, 6, 9, 12, 18, 24 month)
Sponsors
University of Tsukuba
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) malignancy patients in the face of with anthracycline chemotherapy 2) age more than 20 years old 3) EF > 50% 4) life expectancy of > 1year 5) written informed consent
Exclusion criteria
Exclusion criteria: 1) cases with valuvular heart disease, gongenital heart disease, and cardiomyopathy 2) pregnant or lactating women 3) psychotic disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of cardiotoxicity defined as a reduction in left ventricular ejection fraction (LVEF) >10 percentage points from baseline and <50% | — |
Secondary
| Measure | Time frame |
|---|---|
| All cause death, the following cardiac events (cardiac death, acute pulmonary edema, acute coronary syndromes, llife-threatening arrhythmias), the recovery from cadiotoxicity after the initiation of heart failure treatment defined as EF>50% | — |
Countries
Japan
Contacts
Public ContactKazuko Tajiri
University of Tsukuba Hospital Cardiovascular Division
Outcome results
None listed